Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Aprepitant intravenous - Heron Therapeutics

Next Previous
Drug Profile

Aprepitant intravenous - Heron Therapeutics

Alternative Names: APONVIE; Cinvanti; HTX-019

Latest Information Update: 15 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Heron Therapeutics
  • Class Anti-inflammatories; Antidepressants; Antiemetics; Antineoplastics; Antitussives; Antivirals; Fluorobenzenes; Ketones; Morpholines; Skin disorder therapies; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Peptide hydrolase inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chemotherapy-induced nausea and vomiting; Postoperative nausea and vomiting
  • Phase II COVID 2019 infections

Most Recent Events

  • 31 Dec 2024 Aprepitant intravenous (APONVIE) has multiple patent protection in USA, Korea and Japan before December 2023
  • 03 Dec 2024 U.S. District Court dismisses filed against Heron Therapeutics by Fresenius Kabi for Aprepitant intravenous in USA
  • 31 Dec 2023 Aprepitant intravenous has multiple patent protection in USA, Korea and Japan before December 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top